USFDA Inspection Of Granules' Visakhapatnam Unit Concludes With Zero Observations

Granules India’s active pharmaceutical ingredients (API) manufacturing facility in Visakhapatnam, Andhra Pradesh, has completed a U.S. Food and Drug Administration (U.S. FDA) inspection, the company said on Friday.

The Unit IV facility located in Visakhapatnam has successfully completed the U.S. FDA’s pre-approval inspection and GMP audit from June 26-30 with zero [Form 483] observations, the company said.

It also said in the filing that its facility at Jeedimetla (Hyderabad) also completed the US FDA’s surveillance inspection.

From June 26, 2023, through June 30, 2023, there was an audit. The company stated in an exchange filing that the Unit IV plant in Visakhapatnam produces active medicinal ingredients.

Source: Media reports

Top stories
Company

Ashok Leyland Bags Order Worth Rs 982 Cr from MSRTC

3 mins read . 16 Jul 2024 . 05:32 AM

Company

Delta Corp Q1 PAT Declines 68% YoY to Rs 22 crore in FY25

4 mins read . 13 Jul 2024 . 09:30 AM

Company

Zydus Life Gets USFDA Nod for Heart Failure Drug

3 mins read . 13 Jul 2024 . 09:23 AM

Related Blogs
blog-logo

Share Market

blog-logo

12 mins read . 12 Jul 2024

Ritesh Agarwal: The OYO Founder’s Success Story

  • 0 people read
blog-logo

Share Market

blog-logo

15 mins read . 08 Jul 2024

Best Oil & Gas Stocks in India

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions